Development grant
French spin-out TcL Pharma, a specialist in drugs for preventing organ and tissue transplant rejection and treating autoimmune diseases has been awarded a €2.2 million grant by the French National Research Agency, ANR.
This comes just weeks after the company raised €1 million in equity financing as part of France’s TEPA economic stimulus package. TcL Pharma, which is based in Nantes, was spun out of the Institut de Transplantation et de Recherche en Transplantation, the Nantes-based INSERM research institute.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
